Viscoelastic Properties of Lower Extremity Muscles in Patients With Hemophilia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-15

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of our study is to evaluate the viscoelastic properties of lower extremity muscles in patients with hemophilia A and hemophilia B secondarily to compare them with their healthy peers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Emicizumab Treatment in Patients With Hemophilia A

NCT07190118

Hemophilia A Musculoskeletal Assessment Musculoskeletal Abnormalities

NOT_YET_RECRUITING

Sonography and Haemophilia

NCT04550988

Sonography Haemophilia

UNKNOWN

COVID-19 Quarantine on Musculoskeletal Status in Hemophilia

NCT04491318

Hemophilia Arthropathy

COMPLETED

Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens

NCT00927667

Hemophilia A

COMPLETED PHASE4

Multidisciplinary Evaluation of Patients With Hemophilia

NCT02198430

Haemophilia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hemophilia is a rare inherited coagulation disorder that develops as a result of factor VIII (hemophilia A) or factor IX (hemophilia B) deficiency, and is a chronic group of diseases that mainly manifests with intra-articular (hemarthrosis) and intramuscular (hematoma) bleeding, affecting quality of life. The presence of easy ecchymosis formation in early childhood, especially intra-articular and intramuscular spontaneous bleeding, interventions and a history of bleeding that lasted longer than expected after trauma should suggest hemophilia. The severity of bleeding findings is directly related to the degree of deficiency of hemophilia A and B. Hemarthroses due to bleeding in the joint (80%) and hematomas due to intramuscular bleeding (20%) cause joint degeneration and muscle atrophy. The joint in which hemarthrosis is most common is the knee joint, however, bleeding into the lower extremity muscles seriously affects the activities of daily living and lower extremity functionality. For this reason, the researchers aimed to evaluate the viscoelastic properties of lower extremity muscles in hemophilia patients and, secondarily, to compare them with their healthy peers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia Hemophilia A Hemophilia B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hemophilia Group

The viscoelastic properties (tone, stiffness, elasticity) of the lower extremity muscles (Vastus Medialis Obliquus, Rectus Femoris, Vastus Lateralis, Biceps Femoris, Tibialis Anterior, Gastrocnemius) of hemophilia patients who meet the study criteria will be evaluated with the MyotonPro device (Myoton Ltd).

No interventions assigned to this group

Control Group

The viscoelastic properties (tone, stiffness, elasticity) of the lower extremity muscles (Vastus Medialis Obliquus, Rectus Femoris, Vastus Lateralis, Biceps Femoris, Tibialis Anterior, Gastrocnemius) of healthy children meeting the study criteria will be evaluated with the MyotonPro device (Myoton Ltd).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 4-17 years
* Those who have been diagnosed with Hemophilia A and Hemophilia B by a physician
* No history of acute bleeding
* Children who have family consent and volunteer to participate in the study

Exclusion Criteria

* Those with a history of lower extremity surgery
* Those with neurological disease
* Those with a history of lower extremity hemarthrosis or hematoma in the last 1 month
* Patients with inhibitor positive

Minimum Eligible Age

4 Years

Maximum Eligible Age

17 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes